PMID- 37774953
OWN - NLM
STAT- MEDLINE
DCOM- 20231103
LR  - 20240206
IS  - 1873-4995 (Electronic)
IS  - 0168-3659 (Print)
IS  - 0168-3659 (Linking)
VI  - 363
DP  - 2023 Nov
TI  - Experimental and mathematical approaches for drug delivery for the treatment of 
      wet age-related macular degeneration.
PG  - 464-483
LID - S0168-3659(23)00608-9 [pii]
LID - 10.1016/j.jconrel.2023.09.021 [doi]
AB  - Several chronic eye diseases affect the posterior segment of the eye. Among them 
      age-related macular degeneration can cause vision loss if left untreated and is 
      one of the leading causes of visual impairment in the world. Most treatments are 
      based on intravitreally injected therapeutics that inhibit the action of vascular 
      endothelial growth factor. However, due to the need for monthly injections, this 
      method is associated with poor patient compliance. To address this problem, 
      numerous drug delivery systems (DDSs) have been developed. This review covers a 
      selection of particulate systems, non-stimuli responsive hydrogels, implants, and 
      composite systems that have been developed in the last few decades. Depending on 
      the type of DDS, polymer material, and preparation method, different mechanical 
      properties and drug release profiles can be achieved. Furthermore, DDS 
      development can be optimized by implementing mathematical modeling of both drug 
      release and pharmacokinetic aspects. Several existing mathematical models for 
      diffusion-controlled, swelling-controlled, and erosion-controlled drug delivery 
      from polymeric systems are summarized. Compartmental and physiologically based 
      models for ocular drug transport and pharmacokinetics that have studied drug 
      concentration profiles after intravitreal delivery or release from a DDS are also 
      reviewed. The coupling of drug release models with ocular pharmacokinetic models 
      can lead to obtaining much more efficient DDSs for the treatment of age-related 
      macular degeneration and other diseases of the posterior segment of the eye.
CI  - Copyright (c) 2023 The Authors. Published by Elsevier B.V. All rights reserved.
FAU - Chacin Ruiz, Eduardo A
AU  - Chacin Ruiz EA
AD  - Department of Chemical and Biological Engineering, University at Buffalo, The 
      State University of New York, Buffalo, NY, USA.
FAU - Swindle-Reilly, Katelyn E
AU  - Swindle-Reilly KE
AD  - William G. Lowrie Department of Chemical and Biomolecular Engineering, The Ohio 
      State University, Columbus, OH, USA; Department of Biomedical Engineering, The 
      Ohio State University, Columbus, OH, USA; Department of Ophthalmology and Visual 
      Sciences, The Ohio State University, Columbus, OH, USA.
FAU - Ford Versypt, Ashlee N
AU  - Ford Versypt AN
AD  - Department of Chemical and Biological Engineering, University at Buffalo, The 
      State University of New York, Buffalo, NY, USA; Department of Biomedical 
      Engineering, University at Buffalo, The State University of New York, Buffalo, 
      NY, USA; Institute for Artificial Intelligence and Data Science, University at 
      Buffalo, The State University of New York, Buffalo, NY, USA. Electronic address: 
      ashleefv@buffalo.edu.
LA  - eng
GR  - R01 EB032870/EB/NIBIB NIH HHS/United States
GR  - R35 GM133763/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20231004
PL  - Netherlands
TA  - J Control Release
JT  - Journal of controlled release : official journal of the Controlled Release 
      Society
JID - 8607908
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 0 (Hydrogels)
RN  - 0 (Polymers)
SB  - IM
MH  - Humans
MH  - *Vascular Endothelial Growth Factor A
MH  - Drug Delivery Systems/methods
MH  - *Wet Macular Degeneration/drug therapy
MH  - Hydrogels/therapeutic use
MH  - Polymers/therapeutic use
MH  - Intravitreal Injections
PMC - PMC10842193
MID - NIHMS1941105
OTO - NOTNLM
OT  - Drug release modeling
OT  - Intravitreal administration
OT  - Ocular drug delivery
OT  - Pharmacokinetics modeling
OT  - Polymer drug delivery
OT  - Wet age-related macular degeneration
EDAT- 2023/09/30 09:42
MHDA- 2023/11/03 06:43
PMCR- 2024/02/05
CRDT- 2023/09/29 19:16
PHST- 2023/04/07 00:00 [received]
PHST- 2023/09/11 00:00 [revised]
PHST- 2023/09/13 00:00 [accepted]
PHST- 2023/11/03 06:43 [medline]
PHST- 2023/09/30 09:42 [pubmed]
PHST- 2023/09/29 19:16 [entrez]
PHST- 2024/02/05 00:00 [pmc-release]
AID - S0168-3659(23)00608-9 [pii]
AID - 10.1016/j.jconrel.2023.09.021 [doi]
PST - ppublish
SO  - J Control Release. 2023 Nov;363:464-483. doi: 10.1016/j.jconrel.2023.09.021. Epub 
      2023 Oct 4.